INTERLEUKIN 8 PROMOTER POLYMORPHISM PREDICTS THE INITIAL RESPONSE TO BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
In Brief Purpose: To study the association of single-nucleotide polymorphisms of interleukin 8, vascular endothelial growth factor, erythropoietin, complement factor H, complement component C3, and LOC387715 genes with the response to bevacizumab treatment in exudative age-related macular degeneration. Methods: Clinical records, smoking history, optical coherence tomography, and angiographies of 96 bevacizumab-treated exudative age-related macular degeneration patients were analyzed retrospectively. Blood DNA was collected. Based on the disappearance of intra- or subretinal fluid in optical coherence tomography, patients were graded as responders, partial responders, or nonresponders after 3 initial treatment visits and a median time of 3.5 months. Results: Interleukin 8 promoter polymorphism −251A/T was significantly associated with persisting fluid in optical coherence tomography. The A allele was more frequent in nonresponders than in responders (P = 0.033). In multivariate modeling, the AA genotype of −251A/T (P = 0.043) and occult (P = 0.042) or predominantly classic (P = 0.040) lesions predicted poorer outcome. Visual acuity change was better in responders than in nonresponders (P = 0.006). Baseline lesion size (P = 0.006) and retinal cysts after the treatment (P < 0.001) correlated with less visual acuity gain. Conclusion: The A allele and the homozygous AA genotype of interleukin 8 −251A/T were associated with anatomical nonresponse to bevacizumab treatment. The genotype AA of interleukin 8 promoter polymorphism −251A/T was associated with persisting intra- or subretinal fluid in exudative age-related macular degeneration patients after the initial treatment with intravitreal bevacizumab. Interleukin 8 seems to modulate the response to anti–vascular endothelial growth factor therapy at least during the first months of the .treatment
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
Lee, A. Y., Raya, A. K., Kymes, S. M., Shiels, A., & Brantley, M. A. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.150995 · Cited by 134
Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD
Kloeckener-Gruissem, B., Barthelmes, D., Labs, S., Schindler, C., Kurz-Levin, M., Michels, S., Fleischhauer, J., Berger, W., Sutter, F., & Menghini, M. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6080 · Cited by 120 · cited 1×
“In a study of ranibizumab treatment response, patients heterozygous for both polymorphisms CFH Y402H and frizzled homolog 4 (FZD4, rs10898563) seemed more likely to have a favorable outcome.(25) Poor visual acuity response with ranibizumab treatment has also been seen in homozygous carriers of S in LOC387715 A69S.”
BackgroundMcKibbin, M., Ali, M., Bansal, S., Baxter, P. D., West, K., Williams, G., Cassidy, F., & Inglehearn, C. F. (2012) · British Journal of Ophthalmology · doi:10.1136/bjo.2010.193680 · Cited by 100
Interleukin-8 promoter polymorphism -251A/T is a risk factor for age-related macular degeneration
Goverdhan, S. V., Ennis, S., Hannan, S. R., Madhusudhana, K. C., Cree, A. J., Luff, A. J., & Lotery, A. J. (2008) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.123190 · Cited by 79 · cited 9×
“They found that chronic oxidative stress may cause retinal pigment epithelial cells to produce high levels of IL-8 that stimulate inflammation and angiogenesis and in turn may lead to the development of CNV and exudative AMD.44 In AMD patients, IL-8 levels with levels of IL-6 in aqueous humor have correlated with the…”
BackgroundInfluentialInterleukin gene polymorphisms in age-related macular degeneration
Tsai, Y.-Y., Lin, J.-M., Wan, L., Lin, H.-J., Tsai, Y., Lee, C.-C., Tsai, C.-H., Tsai, F.-J., & Tseng, S.-H. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.07-0125 · Cited by 69
Immonen, I., Seitsonen, S., Tommila, P., Kangas-Kontio, T., Kakko, S., Savolainen, E.-R., Savolainen, M. J., & Liinamaa, M. J. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.037 · Cited by 45
Self-citation
Cited by
Wu, M., Xiong, H., Xu, Y., Xiong, X., Zou, H., Zheng, M., Wang, X., & Zhou, X. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309418 · Cited by 36
Chen, G., Tzekov, R., Li, W., Jiang, F., Mao, S., & Tong, Y. (2015) · Scientific Reports · doi:10.1038/srep14517 · Cited by 31
Wang, Z., Zou, M., Chen, A., Liu, Z., Young, C. A., Wang, S., Zheng, D., & Jin, G. (2022) · Acta Ophthalmologica · doi:10.1111/aos.14970 · Cited by 22
Metadata
- Authors
- Hautamäki, A., Kivioja, J., Vavuli, S., Kakko, S., Savolainen, E.-R., Savolainen, M. J., Liinamaa, M. J., Seitsonen, S., Onkamo, P., Järvelä, I., & Immonen, I.
- Venue
- Retina
- Published
- 2013-10
- Volume
- 33
- Issue
- 9
- Pages
- 1815-1827
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2075304664
- Cited by
- 35
- References
- 7
- FWCI
- 4.22
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: INTERLEUKIN 8 PROMOTER POLYMORPHISM PREDICTS THE INITIAL RESPONSE TO BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. https://app.cochat.ai/papers/10.1097/iae.0b013e318285cf92
- The paper
- Hautamäki, A., Kivioja, J., Vavuli, S., Kakko, S., Savolainen, E.-R., Savolainen, M. J., Liinamaa, M. J., Seitsonen, S., Onkamo, P., Järvelä, I., & Immonen, I. (2013). INTERLEUKIN 8 PROMOTER POLYMORPHISM PREDICTS THE INITIAL RESPONSE TO BEVACIZUMAB TREATMENT FOR EXUDATIVE AGE-RELATED MACULAR DEGENERATION. Retina. https://doi.org/10.1097/iae.0b013e318285cf92
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.